© 2020 – 2024 AEA3 WEB | AEAƎ United Kingdom News
AEA3 WEB | AEAƎ United Kingdom News
Image default
News

Experts urge health regulators to approve ‘turning point’ dementia drugs

As results show 35% slowing in cognitive decline, health leaders say swift decisions crucial

  • What impact will the Alzheimer’s drug donanemab have?

Health regulators are being urged to rapidly approve two gamechanging dementia drugs in order to ensure millions of people who could benefit are not “left in limbo”, after yet more stunning trial data.

The final results from a landmark study confirmed that donanemab, made by Eli Lilly, slowed cognitive decline in Alzheimer’s patients by 35%. Trial results published last year showed that a second drug, lecanemab, made by Eisai and Biogen, reduced the rate by 27%.

Continue reading…

Related posts

Sajid Javid’s advice to not ‘cower’ from Covid provokes backlash

AEA3

Teachers in England ‘should pick vulnerable pupils for early return’

AEA3

Trump impeachment trial: defense claims case ‘preposterously wrong on the facts’ – live

AEA3